|Table of Contents|

Advances in research of olanzapine in preventing chemotherapy-induced nausea and vomiting

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
163-169
Research Field:
Publishing date:

Info

Title:
Advances in research of olanzapine in preventing chemotherapy-induced nausea and vomiting
Author(s):
GAO Jiali1; 2; LI Quanfu2; JIANG Caihong2; CHEN Feng2; ZHAO Jun2; ZHAO Lanzhen2; DENG Shuqin2; WANG Wenjuan2; Wuyungaowa2; JIN Gaowa2
1.Ordos School of Clinical Medicine，Inner Mongolia Medical University，Inner Mongolia Ordos 017000，China；2.Ordos Central Hospital，Inner Mongolia Ordos 017000，China.
Keywords:
CINV; olanzapine; prevention; economic effect
PACS:
R730.5
DOI:
10.3969/j.issn.1672-4992.2021.01.037
Abstract:
5-hydroxytryptamine 3 receptor antagonists (5-HT3 RA)，neurokinin-1 receptor antagonists (NK-1 RA)，dexamethasone are commonly used chemotherapy antiemetic drugs.Multinational antiemetic guidelines recommend the combination of the triple regimens.However，the controlling of chemotherapy-induced nausea and vomiting (CINV) is undesirable.In February 2017，olanzapine combined with the adove triple prevention regimens is included in the antiemetic guidelines by NCCN.Clinical studies have confirmed that the low-dose olanzapine 5 mg/day combination regimen has a good efficacy in the prevention of CINV，especially the delayed nausea.Olanzapine has been paid more attention at home and abroad because of its good effectiveness，safety and economy.The progress of olanzapine in preventing CINV is reviewed.

References:

［1］上海市抗癌协会癌症康复与姑息专业委员会.化疗所致恶心呕吐全程管理上海专家共识(2018年版)［J］.中国癌症杂志，2018，28(12)：946-960. Cancer Rehabilitation and Palliative Professional Committee of Shanghai Anti-Cancer Association.Shanghai expert consensus on full management of nausea and vomiting caused by chemotherapy(2018)［J］.China Oncology，2018，28(12)：946-960.
［2］YU KD，HUANG S，ZHANG JX，et al.Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer：A systematic review and meta-analysis［J］.BMC Cancer，2013，13(1)：240.
［3］董爽，王俊，胡胜，等.女性肺癌和乳腺癌患者中阿瑞匹坦与奥氮平预防多日化疗所致延迟性恶心呕吐的疗效观察［J］.肿瘤防治研究，2017，44(05)：356-359. DONG S，WANG J，HU S，et al.Aprepitant versus olanzapine for prevention of nausea and vomiting induced by multiday chemotherapy in female lung cancer or breast cancer patients［J］.Cancer Res Prev Treat，2017，44(05)：356-359.
［4］NAVARI RM，GRAY SE，KERR AC.Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting：a randomized phase Ⅲ trial［J］.The Journal of Supportive Oncology，2011，9(5)：188-195.
［5］CABALEIRO T，LPEZ-RODRíGUEZ R，OCHOA D，et al.Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects［J］.Human Psychopharmacology，2013，28(3)：205-214.
［6］NAVARI RM.Management of chemotherapy-induced nausea and vomiting focus on newer agents and new uses for older agents［J］.Drugs，2013，73(3)：249-262.
［7］PIRL WF，ROTH AJ.Remission of chemotherapy-induced emesis with concurrent olanzapine treatment：A case report［J］.Psycho-Oncology，2000，9(1)：84-87.
［8］PASSIK SD，NAVARI RM，JUNG SH，et al.A phase I trial of olanzapine(zyprexa) for the prevention of delayed emesis in cancer patients：A hoosier oncology group study［J］.Cancer Investigation，2004，22(3)：383-388.
［9］NAVARI RM，EINHORN LH，PASSIK SD，et al.A phase Ⅱ trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting：A hoosier oncology group study［J］.Supportive Care in Cancer，2005，13(7)：529-534.
［10］NAVARI RM，EINHORN LH，LOEHRER PJ，et al.A phase Ⅱ trial of olanzapine，dexamethasone，and palonosetron for the prevention of chemotherapy-induced nausea and vomiting：A hoosier oncology group study［J］.Supportive Care in Cancer，2007，15(11)：1285-1291.
［11］赵瑾，李兴德，高敬华，等.奥氮平预防中、高致吐化疗药物所致恶心、呕吐的临床观察［J］.现代肿瘤医学，2014，22(08)：1941-1943. ZHAO J，LI XD，GAO JH，et al.Clinical observation of olanzapine for prevention of high and moderate emetic risk chemotherapy-induced nausea and vomiting［J］.Modern Oncology，2014，22(08)：1941-1943.
［12］CHELKEBA L，GIDEY K，MAMO A，et al.Olanzapine for chemotherapy-induced nausea and vomiting：systematic review and meta-analysis［J］.Pharmacy Practice(Granada)，2017，15(1)：877.
［13］HESKETH PJ，BOHLKE K，LYMAN GH，et al.Antiemetics：American society of clinical oncology focused guideline update［J］.J Clin Oncol，2015，34(4)：381.
［14］HERRSTEDT J，ROILA F，WARR D，et al.2016 updated MASCC/ESMO consenus recommendations：Prevention of nausea and vomiting following high emetic risk chemotherapy［J］.Support Care Cancer,2017，25(1)：277-288.
［15］SCHWARTZBERG L，HARROW B，LAL LS，et al.Resource utilization for chemotherapy induced nausea and vomiting events in patients with solid tumors treated with antiemetic regimens［J］.Am Health Drug Benefts，2015，8(5)：273-282.
［16］周冬爱，马进安，赵颜忠，等.奥氮平预防高致吐性化疗方案致恶心呕吐的临床观察［J］.临床肿瘤学杂志，2017，22(05)：436-440. ZHOU DA，MA JA，ZHAO YZ，et al.Clinical observation of olanzapine in prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogetic chemotherapy［J］.Chin Clin Oncol，2017，22(05)：436-440.
［17］TIENCHAIANANDA P，NIPONDHKIT W，MANEENIL K，et al.A randomized，double-blind，placebo-controlled study evaluating the efficacy of combination olanzapine，ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide［J］.Annals of Palliative Medicine，2019，8(4)：372-380.
［18］HESKETH PJ，GRUNBERG SM，GRALLA RJ，et al.The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting：A multinational，randomized，double-blind，placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group［J］.J Clin Oncol，2003，21(22)：4112-4119.
［19］POLIBIGELLI S，RODRIGUESPEREIRA J，CARIDES AD，et al.Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting:Results from a randomized，double-blind，placebo-controlled trial in Latin America［J］.Cancer，2003，97(12)：3090-3098.
［20］SHIVAPRAKASH G，UDUPA KARTHIK S，SARAYU V，et al.Olanzapine versus aprepitant for the prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving doxorubicin-cyclophosphamide regimen：A prospective，nonrandomized，open-label study［J］.Indian Journal of Pharmacology，2017，49(6)：451-457.
［21］LI QF，WANG WJ，CHEN G，et al.Evaluation of a neurokinin-1 antagonist in preventing multiple-day cisplatin-induced nausea and vomiting［J］.Open Medicine，2018，13：29-34.
［22］LI QF，Wuyungaowa，WANG WJ，et al.Effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment for multiple-day anthracycline-induced nausea and vomiting［J］.Current Problems in Cancer，2019，43(6)：100462.
［23］LOUIS BN，JANA P，MARIO A，et al.Central nervous system cancers，version 2.2014［J］.J Natl Compr Canc Netw，2014，12(11)：1517-1523.
［24］WANG XF，FENG Y，CHEN Y，et al.A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting［J］.Scientific Reports，2014，4：4813.
［25］COHEN L，MOOR CAD，EISENBERG P，et al.Chemotherapy-induced nausea and vomiting-incidence and impact on patient quality of life at community oncology settings［J］.Supportive Care in Cancer，2007，15(5)：497-503.
［26］BLOECHLDAUM B，DEUSON RR，MAVROS P，et al.Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment［J］.J Clin Oncol，2006，24(27)：4472-4478.
［27］NAVARI RM，QIN R，RUDDY KJ，et al.Olanzapine for the prevention of chemotherapy-induced nausea and vomiting［J］.New England Journal of Medicine，2016，375(2)：134-142.
［28］MASAKAZU A，YUKA K，NOBUHIRO K，et al.Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy［J］.BioMed Research International，2015，2015：1-6.
［29］ABE M，HIRASHIMA Y，KASAMATSU Y，et al.Efficacy and safety of olanzapine combined with aprepitant，palonosetron，and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer：KCOG-G1301 phase Ⅱ trial［J］.Supportive Care In Cancer，2016，24(2)：675-682.
［30］KAZUKI T，NAOKI I，MASATO K，et al.Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting［J］.Cancer Chemotherapy and Pharmacology，2019，84(1)：147-153.
［31］CRYSTAL SD，TARA S，K SCOTT B，et al.Survivorship，version 2.2017，NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw，2017，15(9)：1140-1163.
［32］BASCH E，PRESTRUD AA，HESKETH PJ，et al.Antiemetics：American society of clinical oncology clinical practice guideline update［J］.J Clin Oncol，2011，29(31)：4189-4198.
［33］ROILA F，MOLASSIOTIS A，HERRSTEDT J，et al.2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients［J］.Ann Oncol，2016，27(suppl 5)：v119-v133.
［34］JORDAN K，JAHN F，AAPRO M.Recent developments in the prevention of chemotherapy-induced nausea and vomiting(CINV)：A comprehensive review［J］.Annals of Oncology，2015，26(6)：1081-1090.
［35］ITO Y，KARAYAMA M，INUI N，et al.Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy［J］.Lung Cancer，2014，84(3)：259-264.
［36］BERGER MJ，ETTINGER DS，ASTON J，et al.NCCN guidelines insights：Antiemesis，version 2.2017［J］.J Natl Compr Canc Netw，2017，15(7)：883-893.
［37］吴烜，童刚领，程勃然，等.奥氮平三联止吐方案对接受中度致吐化疗方案的高风险消化道肿瘤患者的止吐疗效研究［J］.肿瘤综合治疗电子杂志，2019，5(03)：49-55. WU X，TONG GL，CHENG BR，et al.Olanzapine-triple antiemetic therapy for prevention of nausea and vomiting induced by moderately emetogenic chemotherapy in CINV high-risk patients of gastrointestinal tumor［J］.Journal of Multidisciplinary Cancer Management（Electronic Version），2019，5(03)：49-55.
［38］JEON SY，HAN HS，BAE WK，et al.A randomized，double-blind，placebo-controlled study of the safety and efficacy of olanzapine for the prevention of chemotherapy-induced nausea and vomiting(CINV) in patients receiving moderately emetogenic chemotherapy：results of the korean south west oncology group(KSWOG) study［J］.Cancer Res Treat，2019，51(1)：90-97.
［39］TAN L，LIU J，LIU X，et al.Clinical research of olanzapine for prevention of chemotherapy-induced nausea and vomiting［J］.Journal of Experimental & Clinical Cancer Research，2009，28(1)：131.
［40］MUKHOPADHYAY S，KWATRA G，PAMELA AK，et al.Role of olanzapine in chemotherapy-induced nausea and vomiting on platinum-based chemotherapy patients：a randomized controlled study［J］.Supportive Care Cancer，2016，25(1)：1-10.
［41］刘雷，丁琛琛，王俊，等.小剂量奥氮平改善女性肺癌患者高致吐性化疗导致的延迟性恶心和呕吐［J］.肿瘤学杂志，2017，23(03)：251-253. LIU L，DING CC，WANG J，et al.Low dose olanzapine alleviates delayed nausea and vomiting induced by highly emetogenic chemotherapv in female lung cancer patients［J］.J Chin Oncol，2017，23(03)：251-253.
［42］YANAI T，IWASA S，HASHIMOTO H，et al.A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy［J］.In J Clin Oncol，2018，23(2)：382-388.
［43］HASHIMOTO H，ABE M，NAKAO M，et al.A randomized，double-blind，placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy：J-FORCE study［J］.J Clin Oncol，2018，48(10)：950-952.
［44］MIZUKAMI N，YAMAUCHI M，KOIKE K，et al.Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy：A randomized，double-blind，placebo-controlled study［J］.Journal of Pain & Symptom Management，2014，47(3)：542-550.
［45］刘益民，朱林，董婷婷，等.奥氮平防治顺铂化疗致恶心呕吐的临床观察［J］.临床肿瘤学杂志，2017，22(11)：1031-1034. LIU YM，ZHU L，DONG TT，et al.Clinical observation of olanzapine in the prevention and treatment of nausea and vomiting caused by cisplatin-based chemotherapy［J］.Chin Clin Oncol，2017，22(11)：1031-1034.
［46］CHIU L，CHIU N，CHOW R，et al.Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting(CINV)：A retrospective study［J］.Annals of Palliative Medicine，2016，5(3)：172-178.
［47］NAVARI RM，NAGY CK，GRAY SE.The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy［J］.Supportive Care in Cancer，2013，21(6)：1655-1663.
［48］NAKAGAKI M，BARRAS M，CURLEY C，et al.A randomized trial of olanzapine versus palonosetron versus infused ondansetron for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation［J］.Supportive Care in Cancer，2017，25(2)：607-613.
［49］程艳霞，邹敏，任林，等.奥氮平所致不良反应文献分析［J］.中国医院药学杂志，2012，32(24)：2022-2024. CHENG YX，ZOU M，REN L，et al.Literature analysis of adverse reactions caused by olanzapine［J］.Chinese Journal of Hospital Pharmacy，2012，32(24)：2022-2024.
［50］LORUSSO V，SPEDICATO A，PETRUCELLI L，et al.Single dose of palonosetron plus dexamethasone to control nausea，vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy(HEC):Preliminary results［J］.Supportive Care in Cancer，2009，17(12)：1469-1473.
［51］石亚飞，陈伟，王会凌，等.两种止吐药物预防CINV的循证药物经济学评价［J］.临床药物治疗杂志，2018，16(09)：20-24,34. SHI YF，CHEN W，WANG HL，et al.The evidence-based pharmacoeconomics evaluation of two kind of antiemetics in the prevention of chemotherapy-induced nausea and vomiting［J］.Clinical Medication Journal，2018，16(09)：20-24,34.
［52］SUTHAN C，HENG LY，SUPHAT S，et al.Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in southeast Asia：A multinational study［J］.Supportive Care in Cancer，2019，27(3)：1109-1119.
［53］MUKOYAMA N，YOSHIMI A，GOTO A，et al.An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in japanese subjects［J］.Biol Pharm Bull，2016，39(11)：1852-1858.
［54］SANOMACHI T，SUZUKI S，KURAMOTO K，et al.Olanzapine，an atypical antipsychotic，inhibits survivin expression and sensitizes cancer cells to chemotherapeutic agents［J］.Anticancer Research，2017，37(11)：6177-6188.

Memo

Memo:
鄂尔多斯市卫健委创新科研项目基金（编号：鄂财社指［2018］64号）；内蒙古医科大学科技百万工程项目基金［编号：YKD2018KJBW(LH)087］
Last Update: 2020-11-30